"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 2 | 6 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 2 | 2 |
| 2023 | 2 | 3 | 5 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Empagliflozin-mediated protection of heparan sulfate-rich endothelial glycocalyx during vascular inflammation. Biochem Pharmacol. 2026 Jul; 249:117890.
-
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. Clin Ther. 2025 Dec; 47(12):1091-1096.
-
The biological effects of bisphenol AF in reproduction and development: What do we know so far? Reprod Toxicol. 2025 03; 132:108857.
-
Prenatal Exposure to Nonpersistent Chemicals and Fetal-to-childhood Growth Trajectories. Epidemiology. 2024 Nov 01; 35(6):874-884.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 08; 38(4):769-770.
-
Recent use of consumer and personal care products and exposures to select endocrine disrupting chemicals among urban children with asthma. J Expo Sci Environ Epidemiol. 2024 Jul; 34(4):637-646.
-
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes. Basic Clin Pharmacol Toxicol. 2024 May; 134(5):643-656.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 02; 38(1):1-3.
-
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation. Curr Opin Pharmacol. 2023 12; 73:102415.
-
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2025 02; 39(1):43-61.